XBIO
NASDAQXenetic Biosciences Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$3.14+0.00 (+0.00%)
01:30 PM07:30 PM
News · 26 weeks20-33%
2025-10-262026-04-19
Mix690d
- SEC Filings2(33%)
- Market2(33%)
- Other1(17%)
- Insider1(17%)
Latest news
25 items- INSIDERInterim CEO and CFO Parslow James F was granted 100,000 shares (SEC Form 4)4 - Xenetic Biosciences, Inc. (0001534525) (Issuer)
- NEWSXenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual MeetingFRAMINGHAM, MA / ACCESS Newswire / April 22, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its abstract has been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 - June 2, 2026, in Chicago, IL. The accepted abstract, titled "Targeting cfDNA and NETs with DNase I to augment CAR T cell function and antitumor efficacy," highlights preclinical research supporting Xenetic's DNase-based therapeutic approach designed to enhance CAR T-cell activit
- SECXenetic Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Xenetic Biosciences, Inc. (0001534525) (Filer)
- NEWSXenetic Biosciences, Inc. Reports Full Year 2025 Financial ResultsEncouraging preclinical and translational data supporting DNase-based approaches to target NETs in difficult-to-treat cancersStrategic focus on investigator-initiated exploratory studies and institutional collaborationsContinued progress toward IND-enabling activities for DNase I programEnded the year with $7.9 million of cash to fund operationsFRAMINGHAM, MA / ACCESS Newswire / March 13, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today reported its financial results for the year ended December 31, 2025.Recent HighlightsExpanded and
- SECSEC Form 10-K filed by Xenetic Biosciences Inc.10-K - Xenetic Biosciences, Inc. (0001534525) (Filer)
- SECSEC Form SCHEDULE 13G filed by Xenetic Biosciences Inc.SCHEDULE 13G - Xenetic Biosciences, Inc. (0001534525) (Subject)
- SECXenetic Biosciences Inc. filed SEC Form 8-K: Other Events8-K - Xenetic Biosciences, Inc. (0001534525) (Filer)
- INSIDERSEC Form 4 filed by Director Borisenko Grigory G.4 - Xenetic Biosciences, Inc. (0001534525) (Issuer)
- INSIDERSEC Form 4 filed by Director Dastoor Firdaus J.4 - Xenetic Biosciences, Inc. (0001534525) (Issuer)
- INSIDERSEC Form 4 filed by Director Kornberg Roger D.4 - Xenetic Biosciences, Inc. (0001534525) (Issuer)
- INSIDERSEC Form 4 filed by Director Vinogradov Alexey Andreevich4 - Xenetic Biosciences, Inc. (0001534525) (Issuer)
- SECSEC Form DEFA14A filed by Xenetic Biosciences Inc.DEFA14A - Xenetic Biosciences, Inc. (0001534525) (Filer)
- SECXenetic Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Xenetic Biosciences, Inc. (0001534525) (Filer)
- NEWSXenetic Biosciences, Inc. Announces Adjournment of 2025 Annual MeetingAdjourns 2025 Annual Meeting of StockholdersUrges Stockholders Who Have Not Voted To Get Votes In FRAMINGHAM, MA / ACCESS Newswire / December 11, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its 2025 Annual Meeting of Stockholders (the "Annual Meeting") was convened and adjourned without any business conducted due to lack of the required quorum.A quorum is necessary to hold the Annual Meeting. There were fewer than a majority of the outstanding shares entitled to vote present, either in person or by proxy, at the
- NEWSXenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase PlatformFRAMINGHAM, MA / ACCESS Newswire / November 19, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced it has executed a 4-month extension of its collaboration with The Scripps Research Institute ("Scripps Research") and the lab of Dr. Alexey Stepanov, Institute Investigator at Scripps Research effective November 1, 2025, to advance the development of the Company's research and development program evaluating the combination of systemic DNase I and CAR T-cell therapies.Xenetic's systemic DNase I candidate, XBIO-015, is currently
- SECXenetic Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Xenetic Biosciences, Inc. (0001534525) (Filer)
- NEWSXenetic Biosciences, Inc. Reports Third Quarter 2025 Financial ResultsContinued execution on collaborations and exploratory investigator-initiated studies with institutional partnersSecured net proceeds of approximately $3.9 million from October 2025 offering FRAMINGHAM, MA / ACCESS Newswire / November 13, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today reported its financial results for the third quarter 2025. "We are steadily building the foundation for potentially transformative progress in the oncology treatment paradigm as we advance our systemic DNase I program in combination with established
- SECSEC Form 10-Q filed by Xenetic Biosciences Inc.10-Q - Xenetic Biosciences, Inc. (0001534525) (Filer)
- SECSEC Form DEFA14A filed by Xenetic Biosciences Inc.DEFA14A - Xenetic Biosciences, Inc. (0001534525) (Filer)
- SECSEC Form DEF 14A filed by Xenetic Biosciences Inc.DEF 14A - Xenetic Biosciences, Inc. (0001534525) (Filer)
- SECXenetic Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - Xenetic Biosciences, Inc. (0001534525) (Filer)
- SECSEC Form 424B5 filed by Xenetic Biosciences Inc.424B5 - Xenetic Biosciences, Inc. (0001534525) (Filer)
- NEWSXenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common StockFRAMINGHAM, MA / ACCESS Newswire / October 10, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced the pricing of an underwritten offering of 735,000 shares of common stock at a price to the public of $6.12 per share, for gross proceeds of approximately $4.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses. All shares of common stock are being offered by Xenetic. The offering is expected to close on or about October 14, 2025, subject to the satisfaction of customary closin
- SECSEC Form 424B5 filed by Xenetic Biosciences Inc.424B5 - Xenetic Biosciences, Inc. (0001534525) (Filer)
- SECXenetic Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Xenetic Biosciences, Inc. (0001534525) (Filer)